

Special Issue

Heterocyclic Chemistry for Cancer and CNS Diseases

Message from the Guest Editor

Heterocycles are prevalent in nature and they have the ability to engage in a wide variety of intermolecular interactions and in biochemical processes; consequently, they play an important role in anti-cancer drug design (65% of the anti-cancer drugs that have received approval from the Food and Drug Administration (FDA) between 2010 and 2015 contain nitrogen-based heterocycles). New heterocyclic compounds have also been developed in the last ten years for the central nervous system (CNS), particularly for the treatment of Alzheimer's disease (AD). Molecular design for the development of cholinesterase (ChEIs) inhibitors, monoaminoxidases (MAOs) inhibitors, NMDA receptor antagonism, etc., involved the exploration of many natural products (their modified derivatives) and also synthetic heterocyclic compounds.

Guest Editor

Prof. Dr. Jean-Pierre Bazureau

Institut des Sciences Chimiques de Rennes (ISCR), UMR CNRS 6226, Groupe CORINT, Université de Rennes 1 (UR1), Campus de Beaulieu, Bât. 10A, 263 Avenue du Général Leclerc, CS 74205, 35042 Rennes CEDEX, France

Deadline for manuscript submissions

closed (28 February 2019)



Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/14999

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)





Pharmaceuticals

an Open Access Journal
by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



[mdpi.com/journal/
pharmaceuticals](https://mdpi.com/journal/pharmaceuticals)



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us. We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Ciências, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)